chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I can't lift my arm any higher than my shoulder; Injection site pain; Injection site swelling; Injection site erythema; muscle pain; Tiredness; headache; shivering; fever; dizziness; This case was reported by a consumer via call center representative and described the occurrence of injected limb mobility decreased in a 55-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 17th April 2019 16:30, the patient received the 1st dose of Shingrix. In April 2019, less than a day after receiving Shingrix, the patient experienced injected limb mobility decreased, injection site pain, injection site swelling, injection site erythema, muscle pain, tiredness, headache, shivering, fever and dizziness. On an unknown date, the outcome of the injected limb mobility decreased, injection site pain, injection site swelling, injection site erythema, muscle pain, tiredness, headache, shivering, fever and dizziness were unknown.   It was unknown if the reporter considered the injected limb mobility decreased, injection site pain, injection site swelling, injection site erythema, muscle pain, tiredness, headache, shivering, fever and dizziness to be related to Shingrix.  Additional case details were provided as follows: The patient received the dose of Shingrix yesterday and the patient not able to lift his arm any higher than the shoulder, had pain , swelling , redness at injection site and all also had other side effects muscle pain, tiredness, headache, shivering, fever and dizziness. The patient enquired that how long should he expect the events. The permission has been given to reporter to contact patient's physician.
The pt experienced 8-10 episodes of blinking eyes and upward eyebrow movements without loss of consciousness without staring and without loss of continence.
Cannot lift arm laterally to even 90 degrees and very little strength to hold there. Pain persists if holding or attempting to lift beyond maybe 40 degrees. Can lift if i go straight out, but to the side.
mom states pt cried for 10PM to 7PM, but slept from 2 to 330; had real high sound for several hrs; no crying when came to office
Information has been received from a bachelor of science in nursing concerning a 13 year old female patient with no allergies and no medical history, who on 22-NOV-2010 was vaccinated with a first dose of GARDASIL (Lot# not reported), IM, and on 29-DEC-2010 was vaccinated with a second dose of GARDASIL (Lot# 666162/0565Z. Exp date 15-SEP-2010), IM. There was no concomitant medication. The nurse reported that on 29-DEC-2010 the patient experienced nausea and hives on her right forearm after receiving second dose of GARDASIL during 15 minutes post administration observation. The patient's mother also reported that on 29-DEC-2010 the patient had experienced brief period of hyperventilation. It was reported that a cold compress was used for the treatment of these symptoms. There were no laboratories performed. At the time of the report the patient's outcome was unknown. The patient sought unspecified medical attention at the time of administration. This is one of two reports received from the same source. Follow up information has been received from the nurse concerning the patient, who on 29-DEC-2010 experienced nausea, hyperventilation and hives on her right forearm which resolved after 15 minutes. The patient's mother indicated that same reactions were observed when the patient received blood work. No further information is available.
Body aches, low grade fever and severe headache. Took ibuprofen.  ( I did have COVID19 July2020).
Pt rcvd vax & exp difficulty swallowing; MD treated pt for a severe ear & throat infect & abdo pain but it was in no way related to vax; addtl MD stated that under no circumstances was pt to recvd dose 3 due to results of hep profile;
low grade fever Shakes Cold numb hands fingers blanch white blood pressure drop 70/40 severe body aches diarrhea nausea
Patient hospitalized within 6 weeks of receiving COVID vaccination. First admission was 3/3/21, second admission was 3/9/21.
Began getting spots on face and head. Spread through Thursday morning and began to look crusty. Dr. Confirmed chicken pox on 10/27 around noon.
Pt w\diabetes mellitus vaccinated w/Recombivax HB entered a study comparing safey & efficacy of hepatitis B (Pre S2+S) vaccine Reocmb & Hepatitis B Vac Recomb in dialysis pt. Was hospitalized because pulmonary edema then sepsis & liver fail
ONE WEEK AFTER VACCINE I DEVELOPED PULSATILE TINNITUS IN RIGHT EAR WHEN LYING DOWN, THEN TWO WEEKS AFTER VACCINE I DEVELOPED BELL'S PALSY ON RIGHT SIDE OF FACE WITH EYE PAIN AND DROOPY EYE LIDS, CHEEK BONES AND MOUTH.  I WENT TO THE EMERGENCY ROOM WHERE THEY PROVIDED THE DIAGNOSIS.
Not sure if related but one month after second dose I was hospitalized with Pericarditis. I was otherwise health prior and no heart issues before.
Dizziness; Feeling flush; "Feeling as if i were having a panic attack"; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7484) via an unspecified route of administration in the left arm on 24Jul2021 at 15:45 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included panic disorder. The patient had no allergies to medications, food and other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Jul2021 at 22:30, the patient experienced dizziness, feeling as if she were having a panic attack and feeling flush. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The patient did not receive any treatment for the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness, "feeling as if having a panic attack" and feeling flush were unknown at the time of this report.
difficulty walking; muscle weakness; balance issues; severe burning pain on his left leg and was diagnosed with shingles; Information has been received from a lawyer regarding a case in litigation and refers to a male patient (pt) of unknown age. No information was provided regarding the pt's medical history, concurrent conditions and concomitant medications. On or around 24-AUG-2017, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (lot number, expiration date, dose, anatomical location and route of administration were not provided) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). On an unknown date, shortly after receiving zoster vaccine live (ZOSTAVAX), the pt suffered severe burning pain on his left leg and was diagnosed with shingles. As a result of the shingles, the pt suffered from difficulty walking, muscle weakness and balance issues requiring extensive physical therapy. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the pt's symptoms resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the vaccination, the pt sustained severe and permanent personal injuries. Further, as a tragic consequence of the vaccination, the pt suffered serious, progressive, permanent and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result, the pt had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of shingles, difficulty walking, muscle weakness and balance issues was considered to be not recovered. The reporter considered the shingles, difficulty walking, muscle weakness and balance issues to be related to zoster vaccine live (ZOSTAVAX). The reporter considered the events to be disabling.
Suspected vaccination failure; got the shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got the shingles).  The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 17-SEP-2023 This case was reported by a patient's wife via interactive digital media. The reporter stated that the vaccine probably helped to not get a bad case of shingles. The reporter's husband received Shingles vaccine and when he got shingles it was a very mild case. Follow-up was not possible as no contact details were available. This case was considered as suspected vaccination failure since the details regarding completion of primary immunization schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.
pt reports p/each hep B vax has had a resp illness w/an onset of 3 days p/vax;each time pt saw pvt MD;1NOV95 devel pneumonia;
FEELS HORRIBLE; THROWING UP; FEVER; This spontaneous report received from a patient concerned a 39 year old female. The patient's weight, height, and medical history were not reported. The patient received macitentan (tablet, route of admin not reported, batch number: Unknown) dose, frequency, and therapy dates were not reported for an unspecified indication. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.  No concomitant medications were reported. On an unspecified date, the subject experienced feels horrible, throwing up, and fever. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 104 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable; and action taken with macitentan was not reported. The outcome of the feels horrible, throwing up and fever was not reported. This report was non-serious.
Approximately 5 minutes after receiving Pfizer bivalent and Fluzone quad, patient felt dizzy and palpitation. upon observation patient's face appeared red. 911 was called. However within a minute patient started feeling better and didn't accept the Epipen. EMT team arrive and checked pt. Patient vital was normal and refuse to go to the hospital. patient was monitored for another 30 minutes. Patient had no additional symptom and confirmed she is feelin fine.
12/23 administered (L) upper arm (TRICEPS). 12/24 developed  redness; swelling pain that increased on 12/25; persists 12.26. No fever. Exam : 11 cm x 7 cm area redness, warmth, swelling, tenderness (L) triceps area plan US to r/o abscess.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender with dialysis. Patient's drug reactions/allergies were not provided. On an unknown date, the patient was vaccinated with the first dose of RECOMBIVAX HB, (40 microgram dialysis formulation) (lot #, expiration date, and route not provided). It was reported that on an unspecified date, the patient received ENGERIX-B (Lot #, expiration date and route not provided) for a second dose. No adverse symptoms reported. Additional information has been requested.
Ist. Dose - Sore arm. No worse than when I receive a Flu shot; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 06Apr2021 14:00 (Lot number: EW0150) at the age of 57 years as single dose for covid-19 immunisation. Relevant medical history included: "Psoriasis/  migraines" (unspecified if ongoing); "Some medications" (unspecified if ongoing); "Psoriasis/  migraines" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 28Apr2021 04:30, outcome "recovering", described as "Ist. Dose - Sore arm. No worse than when I receive a Flu shot". Therapeutic measures were not taken as a result of pain in extremity.  Additional information: Facility where the most recent COVID-19 vaccine was administered was Other. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and no other medications received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient was not tested for COVID-19.   No follow-up attempts are possible. No further information is expected.
Narrative:  COVID infection following COVID vaccine series 05/14 Janssen, dose #1 08/14 pt cc: cough, fever, myalgias, sore throat exposure: unknown 08/15 - 08/23 symptoms continue 08/16 COVID swab, result: detected
Pfizer Dose 1 3/3/21 (EN6204) Pfizer Dose 2 3/24/21 (EP6955) Pfizer Dose 3 8/20/21 (EW0177) COVID Positive 1/30/22  1/30/22: Patient is a 75-year-old male who is immunosuppressed status post right renal transplant (2020) secondary to polycystic kidney disease who presented to ED with complaints of shortness of breath.  Patient has been fully vaccinated against COVID-19 and received his booster. He also tested positive for COVID last October.  Patient recently traveled with his wife who has since tested positive for COVID.  Patient began developing sinus congestion, low-grade fevers and loss of taste and smell. He was tested for COVID on Monday of last week with positive results.  He has been monitoring his pulse ox at home for the past several days and it has been dropping below 90%. He began experiencing shortness of breath yesterday with worsening symptoms today. He denies chest pain. No nausea, vomiting or diarrhea.  He has a past medical history of hypertension, GERD, hyperlipidemia, obstructive sleep apnea and prediabetes.  Patient follows with medical facility for renal transplant and is an on mycophenolate mofetil, prednisone and tacrolimus.  Patient did receive monoclonal antibody infusion 2 days ago.   On arrival to ED patient was hypoxic on room air at 87%, supplemental oxygen was applied any is currently on 4 L saturating around 94%.  Laboratory findings were significant for CKD stage 4 BUN 28 and creatinine 1.34. Hypomagnesemia 1.5.  Given 1 g Mag rider in ED.  D-dimer 0.61.  C reactive 3.60.  Chest x-ray shows new severe airspace disease in both lungs consistent with pneumonia. Unchanged right lower lobe nodule most consistent with granuloma.  EKG normal sinus rhythm, rate 80, QTC 408.  Azithromycin and Rocephin initiated in ED, Decadron 6 mg IV given.  2/5/22: 75-year-old gentleman presented to the emergency room with history of chest pain.  The patient was discharged from the hospital following management focal COVID just 3 days ago prior to admission.  Patient was noted to have troponin trending up, and hence treated for NSTEMI.  Patient to start on heparin drip.  He eventually underwent coronary angiogram with intervention and DES stent.  The patient's symptoms have resolved.  The patient has developed right groin hematoma on the site of catheterization, and as per my review, the hematoma is resolving and lower extremity pulses are within normal range.
pfizer covid-19 bivalent booster was administered to the patient. patient started feeling dizzy and seized a little bit about five minutes after the shot was administered. I also need to mention that he received Moderna for his previous doses. After 15 minutes, he was pretty much A&Ox4. However, 911 was still called to make sure he is completely fine. paramedics ran all different kinds of tests on him and thankfully, he was completely fine and didn't have to be sent to the hospital.
Pt admitted to the hospital with COVID. Pt states that she is vaccinated x2 for COVID plus booster. Unable to obtain manufacturer or dates at this time.
Pt was dizzy and nauseous within 5 minutes of receiving the vaccine.  I had her sit back down in the chair.  I gave her a trash can b/c she thought she might throw up.  She got sweaty and then the feeling passed within 5 minutes.
Approximately 10 minutes after vaccination the patient and her mother came to the pharmacy window stating the patient felt flushed, her throat felt tight and she was pale. I had the patient sit down and gave her juice which she drank immediately. I stayed with her for a few minutes asking if she was feeling better and she confirmed she was. The patient (and mother) were very anxious abut the patient getting the vaccine even prior to vaccination. I observed her from my working station for about 15 more minutes. While the patient was seated the mother inquired about the patient taking a medication if she does have an allergic reaction and we advised she take diphenhydramine if needed. The patient had no history of severe allergy in her lifetime.
early second dose; supposed to be on May 21; local health department who okayed her getting the second dose early because she was leaving; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (early second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (supposed to be on May 21) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (local health department who okayed her getting the second dose early because she was leaving) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (early second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (supposed to be on May 21) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (local health department who okayed her getting the second dose early because she was leaving). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (early second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (supposed to be on May 21) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (local health department who okayed her getting the second dose early because she was leaving) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information provided. Action taken with mRNA-123 is not applicable.
Mouth began tingling; Cheek began to itch; Yellow centered blisters; Rash formed on cheek; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA ORAL (Mouth began tingling), PRURITUS (Cheek began to itch), BLISTER (Yellow centered blisters) and RASH (Rash formed on cheek) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014M20A and 007M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Feb-2021, the patient experienced PARAESTHESIA ORAL (Mouth began tingling), PRURITUS (Cheek began to itch), BLISTER (Yellow centered blisters) and RASH (Rash formed on cheek). At the time of the report, PARAESTHESIA ORAL (Mouth began tingling), PRURITUS (Cheek began to itch) and RASH (Rash formed on cheek) outcome was unknown and BLISTER (Yellow centered blisters) had resolved. Not Provided          No concomitant medications were provided. Treatment medications were unknown.    Most recent FOLLOW-UP information incorporated above includes: On 10-May-2021: Follow-up information received on 10-MAY-2021 contains non-significant information: Contact information updated.
Called to waiting area for client "not feeling well" after having waited for 10 minutes. On arrival, she appeared pale and clammy but was alert. Denies LOC. VS obtained and WNL. Monitored for additional time. VSS and WNL prior to departure. Client feeling better before leaving. Left with spouse driving.
This spontaneous report as received from a healthcare student (with Pharm. D. degree) to a patient of unknown age and gender. Concurrent conditions, medical history and concomitant medications were not specified. On an unknown date 2 years after the 1st dose, the patient was inadvertently vaccinated with the second dose of PNEUMOVAX23 injection, 25/0.5 (dose, route of administration, lot# and expiration date were not reported). No adverse effects reported. Additional information has been requested.
itching, redness, swelling  and discomfort at injection site about a week after injection, lasting  4 days and resolved.
Pt was given DTaP at 12 months, gave another dose at her 18 month visit.
she gets a cough every time she gets a Covid shot or vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID:. The reporter is the patient.  A 69-year-old female patient received bnt162b2 (BNT162B2), in 2022 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COUGH (non-serious) with onset 2022, outcome "unknown", described as "she gets a cough every time she gets a Covid shot or vaccine".  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.
Injection pain; Swelling in arm; Ringing in ear; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (Injection pain), VACCINATION SITE SWELLING (Swelling in arm) and TINNITUS (Ringing in ear) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0378B29) for COVID-19 vaccination.     The patient's past medical history included No adverse event (NO medical history reported).    On 12-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In April 2021, the patient experienced VACCINATION SITE PAIN (Injection pain), VACCINATION SITE SWELLING (Swelling in arm) and TINNITUS (Ringing in ear). At the time of the report, VACCINATION SITE PAIN (Injection pain) and VACCINATION SITE SWELLING (Swelling in arm) had resolved and TINNITUS (Ringing in ear) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications and lab test were not reported   Reporter did not allow further contact